Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Congenital Abnormalities × Gemtuzumab × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 8 Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1 Leukemia, Myeloid, Acute 1 Congenital Abnormalities 1

Interventions

fludarabine phosphate 1 Whole-Body Irradiation 1 Tacrolimus 1 Mycophenolic Acid 1 Miransertib 1 Gemtuzumab 1 Cytarabine 1 Cord Blood Stem Cell Transplantation 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01869803 2018-03-02

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Wake Forest University Health Sciences

Approved for marketing

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡